Five hour geometric mean urinary excretion ratios for 51CrEDTA/L-rhamnose at baseline and on day 7 for subjects who received placebo, rofecoxib 25 mg, rofecoxib 50 mg, and indomethacin 150 mg (per protocol analysis). Indomethacin 150 mg significantly increased the 51CrEDTA/L-rhamnose ratio compared with baseline values, whereas placebo, rofecoxib 25 mg, and rofecoxib 50 mg did not. *p<0.05 versus baseline values